Search Details

Word: inhibitors (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

...long lives. The company is in Phase II trials with LDP341, a proteasome-inhibiting substance that is showing promise against multiple myeloma and chronic lymphocytic leukemia. Phase I studies on the top five solid tumors (breast, pancreatic, prostate, lung and colon) are under way, and at this point the inhibitor seems to be working?at least in mice...

Author: /time Magazine | Title: New Hope For Cancer | 5/28/2001 | See Source »

...Sidransky, an oncologist at Johns Hopkins University, are searching for diagnostics that will pick up other cancers in their preliminary stages. Others are focusing on an even earlier stage, trying to lower the risk of developing cancer to begin with. Here the most exciting work centers on the cycooxygenase inhibitor called COX-2. This pain reliever was originally developed to clamp down on inflammation as aspirin does but without aspirin's tendency to eat through the lining of the stomach...

Author: /time Magazine | Title: New Hope For Cancer | 5/28/2001 | See Source »

...turns out that COX-2 inhibitor drugs also have anticancer effects, reducing the number of precancerous polyps in patients with a hereditary form of colon cancer, perhaps through antiangiogenesis. Scientists are currently studying its effect on noninherited colon cancers. And because the receptor for COX-2 is overexpressed on a range of human cancer types, the hope is that COX-2 inhibitors may be useful in preventing a wider range of cancers, including head and neck, bladder, non-small cell lung and breast cancers...

Author: /time Magazine | Title: New Hope For Cancer | 5/28/2001 | See Source »

...drug could dramatically boost the effectiveness of standard colorectal-cancer chemotherapy, shrinking tumors in more than a fifth of otherwise hopeless cases. Says Sloan-Kettering's Saltz: "The fact that we got a 20% response rate is staggering." What is happening, he surmises, is that the growth-factor inhibitor weakens the tumor enough for chemotherapy to finish...

Author: /time Magazine | Title: New Hope For Cancer | 5/28/2001 | See Source »

Buoyed by those results, Saltz will begin testing IMC-C225 in less advanced patients this summer. And because combination therapy seemed to work so well, he is combining the EGFR inhibitor with not one but two chemotherapy agents to pack a triple punch...

Author: /time Magazine | Title: New Hope For Cancer | 5/28/2001 | See Source »

Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | Next